IQVIA Holdings Inc. (NYSE:IQV) Stake Boosted by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 971,133 shares of the medical research company's stock after buying an additional 14,004 shares during the period. Ameriprise Financial Inc. owned 0.54% of IQVIA worth $190,838,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Aptus Capital Advisors LLC acquired a new stake in IQVIA during the fourth quarter worth about $284,000. Aspire Growth Partners LLC purchased a new position in IQVIA in the fourth quarter worth approximately $241,000. AXA S.A. raised its position in IQVIA by 0.4% in the fourth quarter. AXA S.A. now owns 74,826 shares of the medical research company's stock valued at $14,704,000 after purchasing an additional 318 shares during the period. AlTi Global Inc. purchased a new position in shares of IQVIA during the 4th quarter worth $352,000. Finally, Utah Retirement Systems increased its position in shares of IQVIA by 0.3% during the 4th quarter. Utah Retirement Systems now owns 29,959 shares of the medical research company's stock worth $5,887,000 after purchasing an additional 100 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the subject of several recent research reports. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. HSBC cut IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Citigroup dropped their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Finally, Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $231.71.

IQVIA Stock Down 2.9 %

IQVIA stock traded down $4.39 during midday trading on Friday, hitting $148.90. The stock had a trading volume of 1,677,229 shares, compared to its average volume of 1,468,618. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $25.76 billion, a P/E ratio of 19.85, a P/E/G ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a 12 month low of $135.97 and a 12 month high of $252.88. The business has a fifty day moving average price of $163.91 and a 200 day moving average price of $188.53.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same period last year, the business posted $2.54 earnings per share. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.